FDA Recalls Vitruvias Thyroid Tablets Over Superpotency

FDA classified a nationwide recall of one lot of Vitruvias Therapeutics' Thyroid Tablets, USP 30 mg as Class I on 22 September 2026, its most serious recall category, after testing confirmed the tablets were superpotent. Roughly 1,955 bottles of the affected lot reached patients before Vitruvias pulled it in August. No adverse events have been reported to date. The recall lands on a drug that was never FDA-approved in the first place: desiccated thyroid extract, the animal-derived hormone preparation Vitruvias sells as Thyroid Tablets, USP, has been marketed for decades under a grandfather allowance that predates the modern approval system — a regulatory status this recall does not change, and that endocrinologists have flagged for years as part of why potency problems like this one recur.

What went wrong in one lot

Vitruvias Therapeutics, a specialty pharmaceutical distributor based in Auburn, Alabama, initiated a voluntary recall of Lot 504950 of its Thyroid Tablets, USP 30 mg in August 2026 after testing confirmed the lot was superpotent — stronger than its labeled strength. FDA elevated that recall to Class I, its highest-risk category, on 22 September 2026: a designation the agency reserves for situations where continued use carries a reasonable probability of serious adverse health consequences or death. Roughly 1,955 bottles of the 100-count, 1/2-grain (30 mg) tablets had already reached patients. Vitruvias says it has not received reports of adverse events tied to the lot. A superpotent thyroid preparation pushes patients toward iatrogenic hyperthyroidism — weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or arrhythmia — with FDA specifically naming elderly patients, pregnant patients, and infants as those most vulnerable, particularly if the lot was taken over an extended period before the recall reached them.

A drug FDA has never approved

The detail that gives this recall its context: Thyroid Tablets, USP is not, and has never been, an FDA-approved drug. Desiccated thyroid extract (DTE) — a preparation made from dried, powdered porcine thyroid gland, delivering both levothyroxine (T4) and liothyronine (T3) in a fixed animal-derived ratio — has been sold in the US for more than half a century, grandfathered in from before the modern new-drug-approval framework existed. FDA's own labeling for these products states plainly that they have not been found safe and effective by the agency. That is a different regulatory footing than synthetic levothyroxine, which is FDA-approved and manufactured to a tightly controlled potency specification. It does not mean DTE is unsafe by default, and physicians have prescribed it for decades; it does mean the manufacturing oversight a superpotency failure would normally run into — a validated, FDA-reviewed process — is not the backstop here in the way it is for an approved drug.

Where the two products differ

	Desiccated thyroid extract (Thyroid Tablets, USP)	Synthetic levothyroxine
FDA approval status	Never FDA-approved; marketed under a grandfather allowance	FDA-approved new drug
Hormone content	Fixed T4:T3 ratio from porcine thyroid gland	T4 only, synthetically manufactured
Potency consistency	Batch-to-batch variability is a recognized, recurring issue	Tightly specified and validated per FDA approval
Professional society guidance	American Thyroid Association recommends against routine use	American Thyroid Association's standard first-line therapy

Some patients report better symptom control on DTE than on levothyroxine alone; the comparison above describes regulatory and manufacturing oversight, not a verdict on any individual patient's response.

Why this recall is not a one-off

This is not the first potency-related recall to hit the desiccated thyroid extract category. Acella Pharmaceuticals, another manufacturer of Thyroid Tablets, USP (marketed as NP Thyroid), recalled multiple lots for sub- and superpotency in 2020 and 2021. The American Thyroid Association's own position statement on desiccated thyroid extract points to the underlying mechanism: because DTE is an unregulated animal-derived preparation, the amount of both T4 and T3 can vary from batch to batch, making it harder to keep a patient's levels stable — and making a preparation switch, in either direction, something that requires retitration rather than a simple substitution. FDA has also been reconsidering its regulatory posture toward the whole DTE category; the agency recently withdrew a previously announced August 2026 timeframe for saying more about its approach, leaving the category's long-term regulatory future unresolved.

• Check for the lot: confirm whether any patient currently taking Vitruvias Thyroid Tablets, USP 30 mg has Lot 504950 (NDC 69680-166-00, expiring 30 September 2026).
• Watch for hyperthyroid symptoms in affected patients — tachycardia, new atrial fibrillation, unexplained weight loss, heat intolerance — and check TSH if there is clinical concern, particularly in elderly or pregnant patients.
• Do not switch preparations reflexively. Moving a stable patient off DTE, or between DTE lots or brands, warrants retitration and follow-up labs rather than a same-dose substitution.
• Direct patients with the recalled lot to Vitruvias Therapeutics for a return or replacement, and to their pharmacy or prescriber with any new symptoms.

Frequently asked questions

What exactly did FDA classify as Class I, and when?

One lot (Lot No. 504950, NDC 69680-166-00, expiring 30 September 2026) of Vitruvias Therapeutics' Thyroid Tablets, USP 30 mg (1/2 grain), a desiccated thyroid extract product. Vitruvias initiated the recall in August 2026 after testing confirmed the lot was superpotent; FDA classified it Class I — its most serious level, reserved for a reasonable probability of serious injury or death — on 22 September 2026. Roughly 1,955 bottles of the affected lot reached patients.

Which patients are at greatest risk from a superpotent lot?

FDA and Vitruvias specifically name the elderly, pregnant patients, and infants as most vulnerable to a superpotent thyroid preparation, particularly with extended use. Superpotency pushes patients toward iatrogenic hyperthyroidism: weight loss, heat intolerance, tachycardia and arrhythmia, and hypertension are the findings to watch for, with cardiac risk the most urgent concern in older patients and in pregnancy.

Is Thyroid Tablets, USP an FDA-approved drug?

No. Desiccated thyroid extract products, including Vitruvias' Thyroid Tablets, USP, have never been reviewed and approved by FDA as safe and effective; they remain on the market under a decades-old grandfather allowance for drugs sold before modern approval requirements existed. Synthetic levothyroxine, by contrast, is FDA-approved and manufactured to a tighter potency specification.

Should physicians switch patients on desiccated thyroid extract to levothyroxine?

That is a case-by-case clinical decision, not something this recall settles by itself — some patients report symptom control on desiccated extract that they do not get on levothyroxine alone, and switching itself requires careful dose retitration and monitoring. What the recall does is add one more data point to a known pattern: batch-to-batch potency variability is a structural feature of an unapproved, unstandardized animal-derived product, not a one-off manufacturing accident specific to this lot.